Adocia S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADOIF research report →
About the company
Adocia S. A. , a biotechnology firm founded in Lyon, France, in 2005, operates at the clinical stage, focusing its research and development efforts on optimizing existing therapeutic proteins and peptides for the management of diabetes and various other metabolic conditions.
- CEO
- Olivier Soula
- IPO
- 2014
- Employees
- 97
- HQ
- Lyon, FR
Price Chart
- Market Cap
- $103.66M
- P/E
- -5.26
- P/S
- 59.71
- P/B
- 58.57
- EV/EBITDA
- -5.19
- Div Yield
- 0.00%
- Gross Margin
- -1213.97%
- Op Margin
- -1229.56%
- Net Margin
- -1124.81%
- ROE
- -3796.57%
- ROIC
- -142.92%
- Revenue
- $1.44M · 71.70%
- Net Income
- $-22,754,000 · 2.44%
- EPS
- $-3.22 · 3.59%
- Op Income
- $-19,366,000
- FCF YoY
- 11.17%
- 52W High
- $8.87
- 52W Low
- $8.87
- 50D MA
- $8.87
- 200D MA
- $8.87
- Beta
- 0.72
- Avg Volume
- 0
Get TickerSpark's AI analysis on ADOIF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ADOIF coverage
Recent articles, reports, and earnings notes.
No research on ADOIF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ADOIF report →Similar companies
Peers in the same neighborhood.